ECSP066494A - Composición y método para tratamiento de condiciones uro-genitales - Google Patents

Composición y método para tratamiento de condiciones uro-genitales

Info

Publication number
ECSP066494A
ECSP066494A EC2006006494A ECSP066494A ECSP066494A EC SP066494 A ECSP066494 A EC SP066494A EC 2006006494 A EC2006006494 A EC 2006006494A EC SP066494 A ECSP066494 A EC SP066494A EC SP066494 A ECSP066494 A EC SP066494A
Authority
EC
Ecuador
Prior art keywords
composition
disclosed
uro
usp
treatment
Prior art date
Application number
EC2006006494A
Other languages
English (en)
Inventor
Anna P Catania
James M Lipton
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of ECSP066494A publication Critical patent/ECSP066494A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymerisation Methods In General (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a una composición y método para tratar condiciones uro-genitales. Una incorporación revelada es una composición farmaceútica para uso en el tratamiento de condiciones uro-genitales en la cual dicha composición comprende un regulador KPV, un primer agente conservante, un disolvente, un alcaloide, un polímero acrílico en base a un ácido, un segundo agente conservante y un agente gelatinizante. Otra incorporación de la invención que se revela es la composición que comprende un regulador CKPV (SEQ ID No. 5), API, Carbopol (r), NF, propilparaben, NF; metilparaben, NF; propilene glicol, USP; ácido edítico (EDTA), USP; 2 M solución de hidróxido de sodio (NaOH); y agua estéril para inyección, USP. También se revela los métodos e indicaciones para el uso de la composición revelada
EC2006006494A 2003-09-08 2006-04-07 Composición y método para tratamiento de condiciones uro-genitales ECSP066494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/659,053 US7402559B2 (en) 1999-03-24 2003-09-08 Composition and method of treatment for urogenital conditions

Publications (1)

Publication Number Publication Date
ECSP066494A true ECSP066494A (es) 2006-11-24

Family

ID=34312692

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006494A ECSP066494A (es) 2003-09-08 2006-04-07 Composición y método para tratamiento de condiciones uro-genitales

Country Status (10)

Country Link
US (1) US7402559B2 (es)
EP (1) EP1667703A4 (es)
JP (1) JP2007505045A (es)
CN (1) CN1867349A (es)
AU (1) AU2004272049A1 (es)
CA (1) CA2542303A1 (es)
CR (1) CR8341A (es)
EC (1) ECSP066494A (es)
WO (1) WO2005025503A2 (es)
ZA (1) ZA200602144B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
WO2008157205A2 (en) * 2007-06-15 2008-12-24 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
WO2009062604A2 (en) * 2007-11-02 2009-05-22 Magnus Von Knebel Doeberitz Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
CN101947148A (zh) * 2010-10-11 2011-01-19 中国人民解放军第三军医大学第三附属医院 阴茎感觉增强装置
RU2452490C1 (ru) 2010-12-27 2012-06-10 Виктор Вениаминович Тец Лекарственное средство с активностью против семейства герпес-вирусов
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
RU2530587C1 (ru) * 2013-06-07 2014-10-10 Виктор Вениаминович Тец Способ лечения заболеваний кожи и слизистых оболочек, вызываемых вирусами простого герпеса 1-го и 2-го типов
KR102462510B1 (ko) 2014-08-26 2022-11-01 씨. 알. 바드, 인크. 요로 카테터
RU2605602C1 (ru) 2015-09-15 2016-12-27 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения натриевой соли (2,6-дихлорфенил)амида карбопентоксисульфаниловой кислоты
JP7350722B2 (ja) 2017-09-19 2023-09-26 シー・アール・バード・インコーポレーテッド 尿カテーテルブリッジ装置、そのシステムおよび方法
US12589218B2 (en) 2020-08-03 2026-03-31 C. R. Bard, Inc. Intermittent-catheter assembly and methods thereof
CN116322871A (zh) 2020-09-11 2023-06-23 C·R·巴德股份有限公司 间歇导管组件及其方法
CN112451654A (zh) * 2020-12-10 2021-03-09 兆科药业(广州)有限公司 司来普伐肽的新用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422813A (de) * 1960-11-17 1966-10-31 Ciba Geigy Verfahren zur Herstellung neuer Polypeptide
CH444178A (de) * 1963-05-20 1967-09-30 Ciba Geigy Verfahren zur Herstellung von B-MSH
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
EP0259440B1 (en) * 1986-02-03 1993-01-13 University Patents, Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
CH676425A5 (es) 1986-08-08 1991-01-31 Univ Texas
EP0335662B1 (en) 1988-03-28 1995-07-26 Btg International Limited Peptides
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
JPH0674209B2 (ja) * 1990-09-17 1994-09-21 旭化成工業株式会社 カルバ型カルシトニン類水溶液注射剤の安定化方法
US5795859A (en) 1991-07-05 1998-08-18 Peptide Technology Limited Peptide which abrogates TNF and/or LPS toxicity
JP3628713B2 (ja) 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
JP2500361B2 (ja) 1993-07-14 1996-05-29 工業技術院長 温熱感評価用感覚エレメント
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JP3812957B2 (ja) * 1994-08-02 2006-08-23 森永乳業株式会社 角膜損傷治療剤
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2738746B1 (fr) 1995-09-19 1997-11-14 Oreal Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
FR2781157B1 (fr) 1998-07-15 2000-08-25 Oreal Composition anti-inflammatoire
FR2784028B1 (fr) 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
AU767756C (en) 1999-01-22 2004-08-12 Schepens Eye Research Institute, Inc., The Activation of regulatory T cells by alpha-melanocyte stimulating hormone
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US6803044B1 (en) * 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US7244710B2 (en) * 2002-05-21 2007-07-17 Zengen, Inc. Treatment of ophthalmic infections using antimicrobial peptides
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
EP1191939B1 (en) * 1999-03-24 2007-10-17 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
US7115574B2 (en) * 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system

Also Published As

Publication number Publication date
EP1667703A4 (en) 2009-07-29
WO2005025503A3 (en) 2005-09-22
CA2542303A1 (en) 2005-03-24
CN1867349A (zh) 2006-11-22
JP2007505045A (ja) 2007-03-08
CR8341A (es) 2007-06-08
US7402559B2 (en) 2008-07-22
ZA200602144B (en) 2007-08-29
US20050037032A1 (en) 2005-02-17
WO2005025503A2 (en) 2005-03-24
AU2004272049A1 (en) 2005-03-24
EP1667703A2 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
WO2005025503A3 (en) A composition and method of treatment for urogenital conditions
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
ES2188787T3 (es) Compuesto medicamentoso de micela copolimera y metodo para su preparacion.
BRPI0407882A (pt) conjugados de polìmero-porção de fator viii
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
MA27523A1 (fr) Formulation retard a liberation controlee
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
CO5560558A2 (es) Uso de una composicion de celecoxib para rapido alivio del dolor
CY1118321T1 (el) Συστημα διαλυτων για βελτιωση της διαλυτοτητας των φαρμακευτικων παραγοντων
EA200400154A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ATE359779T1 (de) Selbstemulgierende systeme zur abgabe von taxoiden
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
CN101420934B (zh) 用于使氧化不稳定的组合物稳定的方法
NO20025629D0 (no) Formulering
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
BR0215187A (pt) Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
BR112012007791A2 (pt) método para reticulação de polímeros solúveis em água para uso em aplicação de poços
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger